VGXI Blog & News
Welcome to the VGXI blog where we examine scientific trends, innovation, technological advancements in plasmid DNA manufacturing, and uncover how next-generation therapeutics are shaping the future of medicine and improving patients’ lives.
Global Capabilities Series: Insights from CGT Asia 2025
Interview with Jeff Whitmore, Chief Commercial Officer, on VGXI’s Role in Bridging APAC Innovation and U.S. Commercialization As part of our ongoing commitment to international collaboration, VGXI continues to extend its reach through the Global Capabilities Series, an initiative designed to highlight how regional engagement supports global therapeutic impact. This new blog series centers on[...]
Read More
VGXI Completes Successful FDA Inspection Enabling Client BLA Approval Milestone, Advancing Its Leadership in Plasmid DNA Manufacturing
CONROE, Texas — VGXI, Inc., a leading contract development and manufacturing organization (CDMO) specializing in plasmid DNA biopharmaceuticals, including for use in[...]
Read More
VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies
Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments NASHVILLE, Tenn. and CONROE, Texas, Oct. 15, 2024 /PRNewswire/[...]
Read More
VGXI to Attend Alliance for Regenerative Medicine Annual Meeting on the Mesa
Conroe, Texas – VGXI, Inc., a leading provider of plasmid DNA manufacturing and development services, is proud to announce its[...]
Read More
VGXI accepted as a Member of the Biopharmaceutical Manufacturing Preparedness (BioMap) Consortium
VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and[...]
Read More
VGXI, accepted as a Member of the US Government’s Rapid Response Partnership Vehicle (RRPV)
VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and[...]
Read More
Future Proof Your Advanced Therapies Supply Chain with VGXI’s US-Based Plasmid CDMO Expertise
In the current landscape of biopharmaceutical drug development, finding a reliable and experienced contract development and manufacturing organization (CDMO) partner[...]
Read More
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and[...]
Read More
VGXI’s Expanded Manufacturing Capacity Addresses Plasmid DNA Supply Chain Challenges
Plasmid DNA (pDNA) is an essential part of the supply chain for advanced therapies and personalized medicine, including gene therapies,[...]
Read More
Five Qualities to Look for in a CDMO
As the biopharmaceutical industry increasingly turns to outsourcing, the key to success lies in choosing the right Contract Development and[...]
Read More